Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33,483 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C; FURLONG investigators. Shi Y, et al. Among authors: liu j, liu y, liu c, liu f. Lancet Respir Med. 2022 Nov;10(11):1019-1028. doi: 10.1016/S2213-2600(22)00168-0. Epub 2022 Jun 2. Lancet Respir Med. 2022. PMID: 35662408 Clinical Trial.
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C. Shi Y, et al. Among authors: liu j, liu y, liu c, liu f. J Thorac Oncol. 2022 Nov;17(11):1297-1305. doi: 10.1016/j.jtho.2022.07.1143. Epub 2022 Aug 3. J Thorac Oncol. 2022. PMID: 35932953 Free article. Clinical Trial.
Globally, songs and instrumental melodies are slower and higher and use more stable pitches than speech: A Registered Report.
Ozaki Y, Tierney A, Pfordresher PQ, McBride JM, Benetos E, Proutskova P, Chiba G, Liu F, Jacoby N, Purdy SC, Opondo P, Fitch WT, Hegde S, Rocamora M, Thorne R, Nweke F, Sadaphal DP, Sadaphal PM, Hadavi S, Fujii S, Choo S, Naruse M, Ehara U, Sy L, Parselelo ML, Anglada-Tort M, Hansen NC, Haiduk F, Færøvik U, Magalhães V, Krzyżanowski W, Shcherbakova O, Hereld D, Barbosa BS, Varella MAC, van Tongeren M, Dessiatnitchenko P, Zar SZ, El Kahla I, Muslu O, Troy J, Lomsadze T, Kurdova D, Tsope C, Fredriksson D, Arabadjiev A, Sarbah JP, Arhine A, Meachair TÓ, Silva-Zurita J, Soto-Silva I, Millalonco NEM, Ambrazevičius R, Loui P, Ravignani A, Jadoul Y, Larrouy-Maestri P, Bruder C, Teyxokawa TP, Kuikuro U, Natsitsabui R, Sagarzazu NB, Raviv L, Zeng M, Varnosfaderani SD, Gómez-Cañón JS, Kolff K, der Nederlanden CVB, Chhatwal M, David RM, Setiawan IPG, Lekakul G, Borsan VN, Nguqu N, Savage PE. Ozaki Y, et al. Among authors: liu f. Sci Adv. 2024 May 17;10(20):eadm9797. doi: 10.1126/sciadv.adm9797. Epub 2024 May 15. Sci Adv. 2024. PMID: 38748798
33,483 results
You have reached the last available page of results. Please see the User Guide for more information.